This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potential in future curative treatment strategies.